Circulating CCR6⁺ILC proportions are lower in multiple sclerosis patients.

ABSTRACT:

Objectives

The role of innate lymphoid cells (ILC), particularly helper ILC, in the pathogenesis of multiple sclerosis (MS) is not well understood. Here, we present a comprehensive analysis of peripheral ILC subsets in MS patients prior and after alemtuzumab administration using mass cytometry.

Methods

Circulating ILC were analysed by mass cytometry in MS patients before and after alemtuzumab. These were compared with non-MS controls. MS-related shifts among ILC immunophenotypes were further elucidated by fast interpolation-based t-SNE (Flt-SNE) dimensionality reduction.

Results

Neither natural killer (NK) cells nor helper ILC (ILC1, ILC2 and ILC3) levels were altered following alemtuzumab treatment. However, CD56^bright NK cell expansions were observed in r

SUBMITTER: Aglas-Leitner F 

PROVIDER: S-EPMC9782758 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature